Phaseline

Companies › Compass Therapeutics

Compass Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CTX-009
Bispecific antibody
–Phase 2Biliary Tract Cancer; GlioblastomaAug 2027
CTX-8371
Unclear - mechanism not stated in registry
–Phase 1Non Small Cell Lung CancerDec 2026
CTX-10726–Phase 1Gastroesophageal Cancer (GC)Apr 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06150664CTX-8371Phase 1Non Small Cell Lung CancerOncologyDec 2026
NCT05506943CTX-009Phase 2Biliary Tract CancerOncologyAug 2027
NCT07419841CTX-10726Phase 1Gastroesophageal Cancer (GC)OncologyApr 2028
NCT07392957CTX-009Phase 1GlioblastomaOncologyJun 2029

From the company's SEC filings

Cash and short-term investments of $163m on 2026-09-30; operating cash outflow about $65m a year; runway about 30 months at that burn, to Apr 2029; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Nurix Therapeutics Puma Biotechnology Tianjin ConjuStar Biologics Avistone Biotechnology Day One Biopharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.